CN107669695B - Icariside II is preparing the application in anti-hepatitis B virus product - Google Patents
Icariside II is preparing the application in anti-hepatitis B virus product Download PDFInfo
- Publication number
- CN107669695B CN107669695B CN201711139054.6A CN201711139054A CN107669695B CN 107669695 B CN107669695 B CN 107669695B CN 201711139054 A CN201711139054 A CN 201711139054A CN 107669695 B CN107669695 B CN 107669695B
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- icariside
- virus
- hbv
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Abstract
This patent application discloses icariside IIs to prepare the application in anti-hepatitis B virus product, it is studied by external hepatitis b virus infected cell model experiment, the icariside II can inhibit the expression of hepatitis B virus surface antigen, e antigen as the result is shown, can inhibit the duplication of hepatitis B virus DNA；It is studied by HBV infection mouse model from vivo, shows that the icariside II can reduce HBsAg, HBeAg and HBV DNA level in HBV infection mice serum.It proves that icariside II plays the role of apparent anti-hepatitis virus, can be used for preparing the drug of related disease caused by anti-hepatitis virus infects.
Description
Technical field
The invention belongs to field of traditional Chinese medicine pharmacy, the special monomer icariside II being related in Chinese herbal medicine Herba Epimedii is preparing medicine
Application in compositions, especially icariside II are preparing the purposes in anti-hepatitis B virus product.
Background technique
Diseases related have become of hepatitis type B virus (hepatitis B virus, HBV) threatens human health now
One of principal disease.Mainly there are nucleoside analog and interferon for the antiviral therapy drug of hepatitis B at present.Though these drugs
There is certain curative effect, but there is also adverse reactions, and is also gradually increased for the drug resistance of nucleoside analog.Therefore, novel anti-
The research of HBV drug has prior meaning.
Herba Epimedii (Epimedium brevicornu Maxim) alias HERBA EPIMEDII, thousand liang of gold, Herba Epimediis etc. are small
Bark of a cork tree section barrenwort, is commonly distributed in the ground such as China Guizhou, Sichuan, Liaoning, Jiangxi, Shaanxi, Hunan, Hubei.Herba Epimedii
It records earliest and sees Shennong's Herbal, there is high medical value, applicating history is long, according to records, the master of Herba Epimedii
Effect is wanted to have tonifying kidney and strengthening yang, dispelling wind and eliminating dampness etc..Modern research shows that Herba Epimedii clinically can be used for treating lump in breast, height
The diseases such as blood pressure, there are also enhance immune function of human body, anti-aging, prevention and treatment neurogenic disease.The prior art is such as
A kind of Chinese medicine composition for treating liver-depression and spleen-insufficiency type chronic hepatitis, Chinese medicine material and weight disclosed in CN201510620180.8
Part proportion are as follows: 10-40 parts of Poria cocos, 5-20 parts of Radix Angelicae Sinensis, 5-25 parts of Radix Paeoniae Alba, 5-20 parts of radix bupleuri, 5-20 parts of peppermint, rhizoma atractylodis macrocephalae 10-30
Part, 5-25 parts of stir-baked FRUCTUS GARDENIAE, 5-20 parts of cortex cinnamomi, 5-20 parts of fried atractylodes, fries semen coicis 10-30 parts, Semen Lablab Album 5-25 at 5-20 parts of rhizoma cyperi
Part, 5-20 parts of Cortex Phellodendri, 10-40 parts of the fruit of glossy privet, 5-25 parts of Herba Epimedii, 5-20 parts of thizoma curculiginis, 5-25 parts of Chinese yam, 5-20 parts of Gorgon fruit, vehicle
First sub- 5-20 parts, 10-30 parts of stringy stonecrop, 5-20 parts of rhizoma alismatis, 5-25 parts of wilsonii, 5-20 parts of fennel seeds, 5-25 parts of the calyx and receptacle of a persimmon, melia toosendan
It is 5-20 parts sub-, 5-15 parts of Radix Glycyrrhizae.The traditional Chinese medicine composition for treating liver-depression and spleen-insufficiency type chronic hepatitis of the invention is significant in efficacy, and effect can
It leans on.For another example a kind of traditional Chinese herbal decoction for treating chronic hepatitis, the parts by weight of constitutive material disclosed in CN201510594657.X are as follows:
Polygonum cuspidate 8-10, Radix Curcumae 3-4, rhizoma imperatae 2-3, Herba Apii graveolentis root 5-6, radix scutellariae 9-10, prepared fleece flower root 2-4, witloof 4-6, Bi dial 8-10, vehicle
Preceding grass 3-4, Flos Magnoliae Officinalis 2-4, Herba Epimedii 5-8, day lily 15-20, granatum 10-15, radix boehmeriae 2-4, seed of feather cockscomb 3-4, tree peony
Skin 10-15, florists chrysanthemum seedling 4-6, thin evodia root 1-3；The invention drug matching meets traditional chinese medicine and modern medicine and pharmacology research
It is theoretical；Have effects that promoting blood circulation and removing obstruction in channels, resolving hard lump, clearing heat and detoxicating, supplementing qi and nourishing yin, stomach strengthening and digestion promoting, the traditional Chinese herbal decoction of the invention
It is good effect, quick, convenient to take, without side-effects, there is good therapeutic effect to chronic hepatitis.For another example
A kind of medicament for treating chronic hepatitis B disclosed in CN201210076981.9, it is made of following bulk drugs: half
Lotus, Charred Triplet, Radix Codonopsis, rhizoma alismatis, semen ziziphi spinosae, Radix Isatidis, campanulaceae, Radix Astragali, Radix Angelicae Sinensis, oriental wormwood, herba lysimachiae, Herba Epimedii.The invention institute
The medicament stated is prepared with pure Chinese medicine, using traditional production method, remains the pharmacological property of drug, and curative effect is clear, can effectively control
Treat chronic hepatitis B.But these technologies be Herba Epimedii and other traditional Chinese medicine ingredients are combined to treat it is chronic
Hepatitis, above-mentioned Chinese medicine composition also have an other compositions in addition to Herba Epimedii, therefore are specifically that ingredient works and also has no and drape over one's shoulders
Dew.
The one kind that prior art CN201580055424.0 also discloses contains well Shorthorned Epimedium P.E in Korea and is used as activity
The antiviral composition of ingredient, it includes korean epimedium herb (Epimedium koreanum) extracts as active constituent.Hair
Existing Epimedium koreanum extract increases cell (such as vesicular stomatitis virus, newcastle disease virus, the blister sore being infected
Poison and rhinovirus) cell survival rate, and reduce the viral load in cell.The Epimedium koreanum extract of foregoing invention presses down
Virus multiplication in cell processed, therefore can effectively serve as preventing and treating about vesicular stomatitis virus, newcastle disease
The pharmaceutical composition of virus, the viral disease of herpesviral and rhinovirus, meanwhile, inventor points out that it is drawn in treatment by virus
The application of the oxyhepatitis risen, but have no the virus composition throughout the specification and can be used to prevent and treat oxyhepatitis
Relevant evidence, the active constituent in Shorthorned Epimedium P.E is unknown in addition, therefore the prior art lacks one kind specifically from Herba Epimedii
The ingredient of middle extraction is to treat chronic hepatitis.
Icariside II (icarisid II, Ics II) is a kind of polyhydroxy flavonoids monomer extracted from Herba Epimedii
Ingredient, is one of effective component of Herba Epimedii, document report its there is treatment erectile dysfunction, anti-ischemic brain damage, anti-
The effects of tumour, has no the report in relation to icariside II anti-HBV effect at present.
Summary of the invention
The invention is intended to provide a kind of new application of icariside II, to treat hepatitis b virus infected caused phase
Related disorders.
Icariside II or their pharmaceutically acceptable salts and pharmaceutically acceptable carrier or excipient are being made
The application being ready for use in the product of prevention and/or the treatment liver diseases as caused by hepatitis type B virus
The liver diseases are hepatitis b virus infected caused related disease.
The related disease includes hepatitis B, cirrhosis or liver cancer.
The molecular formula of icariside II of the invention are as follows: C27H30O10, it is C to above-mentioned molecular formula27H30O10Herba Epimedii
Secondary glycosides II has carried out the inside and outside experiment of following bodies:
In vitro study is carried out by the hepatocellular carcinoma H22 .2.15 model to stable transfection HBV full-length genome, is detected excessive
Influence of the sheep leaves of pulse plants time glycosides II to hepatitis B virus surface antigen (hepatitis B surface antigen, HBsAg), to e antigen
The influence of (hepatitis B e antigen, HBeAg) expression, the influence to hepatitis B virus DNA duplication.Testing result shows,
The icariside II is able to suppress the HBsAg of HepG2.2.15 cell secretion；It is able to suppress HepG2.2.15 cell point
The HBeAg secreted；It is able to suppress the duplication of HBV DNA in HepG2.2.15 cell.
The HBV infection mouse model established by 1.2 plasmid of high pressure tail vein injection pAAV HBV studies Herba Epimedii
Influence of the secondary glycosides II to HBsAg, HBeAg and HBV DNA in mice serum.Testing result shows, the icariside II
It can reduce HBsAg, HBeAg and HBV DNA level in HBV infection mice serum.
The results show, the icariside II have apparent Anti-hepatitis B virus effects, can be used for making
The drug of standby resistance of hepatitis B and related liver disease.
Detailed description of the invention
Fig. 1 is the influence schematic diagram that CCK8 method detects that icariside II grows cell；*: and the ICS II of 0 μ g/ml group
Compared to p < 0.05, p < 0.01 * *: is compared with the ICS II of 0 μ g/ml group.
Fig. 2 is to be illustrated with ELISA method detection icariside II to the influence that HepG2.2.15 cell HBsAg secretes
Figure, *: compares p < 0.05, * * with the ICS II of 0 μ g/ml group: comparing p < 0.01 with the ICS II of 0 μ g/ml group.
Fig. 3 is to be illustrated with ELISA method detection icariside II to the influence that HepG2.2.15 cell HBeAg secretes
Figure, *: compares p < 0.05, * * with the ICS II of 0 μ g/ml group: comparing p < 0.01 with the ICS II of 0 μ g/ml group.
Fig. 4 is to detect the influence that icariside II secretes HepG2.2.15 cell HBV DNA with fluorescence quantitative PCR method
*: schematic diagram compares p < 0.05, * * with the ICS II of 0 μ g/ml group: comparing p < 0.01 with the ICS II of 0 μ g/ml group.
Fig. 5 is to be illustrated with ELISA method detection icariside II to the influence that HBsAg in HBV infection mice serum secretes
Figure, *: compares p < 0.05, # with 10 days model groups: comparing p < 0.05 with 20 days model groups.
Fig. 6 is to be illustrated with ELISA method detection icariside II to the influence that HBeAg in HBV infection mice serum secretes
Figure, *: compares p < 0.05, # with 10 days model groups: comparing p < 0.05 with 20 days model groups.
Fig. 7 is to detect icariside II with fluorescence quantitative PCR method to secrete HBV DNA in HBV infection mice serum
Schematic diagram is influenced, *: p < 0.05, # is compared with 10 days model groups: comparing p < 0.05 with 20 days model groups.
Specific embodiment
Below by specific embodiment, the present invention is described in further detail:
Embodiment 1: the In vitro cell model experiment of icariside II
The influence that the present invention grows cell with the method detection drug that CCK8 is analyzed, as shown in Figure 1, using this field reality
Test generally acknowledged HBV infection cell model HepG2.2.15, the icariside II concentration of selection be respectively 5 μ g/ml, 10 μ g/ml,
12.5 μ g/ml, 15 μ g/ml and 20 μ g/ml, experimental data carry out T check analysis, and concentration is excessive greater than 15 μ g/ml as the result is shown
The sheep leaves of pulse plants time glycosides II has apparent influence (p < 0.05) to the growth of HepG2.2.15 cell.
Hepatitis B virus surface antigen (HBsAg) is the main indicator of HBV infection.As shown in Fig. 2, by testing and analyzing cell
The amount of HBsAg in supernatant, the results show that can obviously inhibit HBsAg's when the concentration of icariside II is greater than 6.25 μ g/ml
It secretes (p < 0.01).
Hepatitis B virus e antigen (HBeAg) is the index of hbv replication.By testing and analyzing the amount of HBeAg in cell conditioned medium,
As shown in figure 3, icariside II can obviously inhibit the secretion (p < 0.01) of HBeAg.
The copy number of HBV DNA is that direct reflection virus measures how many indexs in vivo.By testing and analyzing cell conditioned medium
The copy number of middle HBVDNA, as shown in figure 4, icariside II can be substantially reduced the copy number (p < 0.01) of HBV DNA.
The results show, the icariside II have apparent Anti-HBV activity to act on, and can be used for preparing the B-mode liver of prevention and treatment
The drug of related disease caused by scorching virus infection.
Embodiment 2: the HBV infection mouse in vivo models experiment of icariside II
HBV infection mouse model is established by tail vein injection using the HBV plasmid pAAV HBV 1.2 of this field maturation,
With the method for intraperitoneal injection, blood sampling separation serum is detected respectively after administration 10 days and 20 days.
After organism infection HBV, increasing for HBsAg is shown as in peripheral blood at first.By testing and analyzing in mice serum
The amount of HBsAg, as shown in Figure 5: after administration 10 days, icariside II can obviously inhibit the secretion (p < 0.05) of HBsAg, administration
After 20 days, which further enhances (p < 0.05).
HBeAg is a kind of soluble protein, can be free in serum, the growth and decline of growth and decline and virion and DNA polymerase
It is almost the same, it is the index of hbv replication.By testing and analyzing the amount of HBeAg in mice serum, as shown in Figure 6: administration 10 days
Afterwards, icariside II can obviously inhibit the secretion (p < 0.05) of HBeAg, and after administration 20 days, which is further enhanced
(p<0.05)。
By testing and analyzing the copy number of HBV DNA in mice serum, as shown in Figure 7: after administration 10 days, icariside
II can be substantially reduced the copy number (p < 0.05) of HBV DNA.
The results show, the icariside II have apparent Anti-HBV activity to act on, and can be used for preparing the B-mode liver of prevention and treatment
The drug of related disease caused by scorching virus infection.
What has been described above is only an embodiment of the present invention, and the common sense such as well known specific structure and characteristic are not made herein in scheme
Excessive description, technical field that the present invention belongs to is all before one skilled in the art know the applying date or priority date
Ordinary technical knowledge can know the prior art all in the field, and have using routine experiment hand before the date
The ability of section, one skilled in the art can improve and be implemented in conjunction with self-ability under the enlightenment that the application provides
This programme, some typical known features or known method should not become one skilled in the art and implement the application
Obstacle.It should be pointed out that for those skilled in the art, without departing from the structure of the invention, can also make
Several modifications and improvements out, these also should be considered as protection scope of the present invention, these all will not influence the effect that the present invention is implemented
Fruit and patent practicability.The scope of protection required by this application should be based on the content of the claims, the tool in specification
The records such as body embodiment can be used for explaining the content of claim.
Claims (3)
1. prepared by icariside II or their pharmaceutically acceptable salts and pharmaceutically acceptable carrier or excipient
The application in product for preventing and/or treating the liver diseases as caused by hepatitis type B virus.
2. application according to claim 1, it is characterised in that: the liver diseases are hepatitis b virus infected caused
Related disease.
3. application according to claim 2, it is characterised in that: the related disease include hepatitis B, cirrhosis or
Liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711139054.6A CN107669695B (en) | 2017-11-16 | 2017-11-16 | Icariside II is preparing the application in anti-hepatitis B virus product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711139054.6A CN107669695B (en) | 2017-11-16 | 2017-11-16 | Icariside II is preparing the application in anti-hepatitis B virus product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107669695A CN107669695A (en) | 2018-02-09 |
| CN107669695B true CN107669695B (en) | 2019-07-16 |
Family
ID=61149563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711139054.6A Active CN107669695B (en) | 2017-11-16 | 2017-11-16 | Icariside II is preparing the application in anti-hepatitis B virus product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107669695B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419863A (en) * | 2020-04-01 | 2020-07-17 | 广州中医药大学(广州中医药研究院) | Application of baohuoside I in preparation of CXC L1 activity inhibitor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102008533A (en) * | 2010-12-06 | 2011-04-13 | 吉林修正药业新药开发有限公司 | Medicinal application and preparation method of shorthorned epimedium P.E |
| CN104825479A (en) * | 2015-05-20 | 2015-08-12 | 佛山市金骏康健康科技有限公司 | Icariside derivatives as well as preparation method and application thereof in promoting human cells to generate interferon-gamma and treating disease |
| CN106511847A (en) * | 2015-09-10 | 2017-03-22 | 刘山海 | Traditional Chinese medicines formula for treating hepatitis B |
-
2017
- 2017-11-16 CN CN201711139054.6A patent/CN107669695B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102008533A (en) * | 2010-12-06 | 2011-04-13 | 吉林修正药业新药开发有限公司 | Medicinal application and preparation method of shorthorned epimedium P.E |
| CN104825479A (en) * | 2015-05-20 | 2015-08-12 | 佛山市金骏康健康科技有限公司 | Icariside derivatives as well as preparation method and application thereof in promoting human cells to generate interferon-gamma and treating disease |
| CN106511847A (en) * | 2015-09-10 | 2017-03-22 | 刘山海 | Traditional Chinese medicines formula for treating hepatitis B |
Non-Patent Citations (1)
| Title |
|---|
| 淫羊藿苷及其代谢产物淫羊藿次苷II对骨髓间质干细胞成骨性分化影响的比较研究;翟远坤;《中药材》;20101225;第33卷(第12期);1896-1900 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107669695A (en) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107303384A (en) | It is a kind of to have medicable Chinese medicine composition and its derivative and product to a variety of symptoms | |
| CN101347612A (en) | Compound medicament for treating common cold cough and acute/chronic bronchitis, and preparation method thereof | |
| CN103550506B (en) | A kind of in radiotherapy with the use of Chinese medicine composition | |
| CN105561006B (en) | One kind having treatment alcoholic liver disease function medicament composition and its preparation method and application | |
| CN107669695B (en) | Icariside II is preparing the application in anti-hepatitis B virus product | |
| CN109276591A (en) | Wilsonii Radix Angelicae Sinensis Milkvetch root composition auxiliary hyperglycemic new application | |
| CN109512857A (en) | A kind of mannose-Chinese herbal compounds inhibiting tumour growth | |
| CN102988764B (en) | Chinese medicinal preparation for resisting coccidiosis and preparation method thereof | |
| CN102698100B (en) | Oral solution for treating diabetes mellitus | |
| CN104606494A (en) | Traditional Chinese medicine for treating liver cancer and preparation method thereof | |
| CN104225502A (en) | Obstetrics and gynecology drug for treating endocrine dyscrasia and preparation method thereof | |
| CN1056755C (en) | Medicine of curing hepatitis | |
| CN101095731A (en) | Chinese traditional medicine for preventing and treating rheum | |
| CN107029173B (en) | Pharmaceutical composition for treating primary liver cancer | |
| CN102872385B (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN104306803A (en) | Traditional Chinese medicine composition for treating minimal residual leukemia | |
| CN101224226B (en) | Novel clinical uses of big nilgiri nettle | |
| CN104288514A (en) | Traditional Chinese medicine for treating hyperthyroidism | |
| CN114558074A (en) | Traditional Chinese medicine composition for treating metabolic-related fatty liver disease and preparation method and application thereof | |
| CN103272176A (en) | Traditional Chinese medicine composition for treating cardiovascular disease and preparation method thereof | |
| CN1191086C (en) | Medicine for treating cold in summer and autumn | |
| CN104524171A (en) | Application of traditional Chinese medicine preparation in preparing medicine for treating hepatitis | |
| CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
| CN104689088B (en) | A kind of Chinese medicine preparation and preparation method of prevention immunosenescence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: No. 201 Dalian Road, Zunyi City, Guizhou Province, 563000 Applicant after: Zunyi Medical University Address before: 563000 No. 201 Dalian Road, Huichuan District, Zunyi City, Guizhou Province Applicant before: Zunyi Medical College |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |